Building a CAR-T CMC Strategy on a Limited Budget - Summary - MDSpire

Building a CAR-T CMC Strategy on a Limited Budget

Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes

By
Kate Fynes
October 6, 2026
8 min

The Medicine Maker

Share

Original Source(s)

The Medicine Maker

Building a CAR-T CMC Strategy on a Limited Budget

by Kate Fynes
October 6, 2026

Related Content

The Analytical Scientist

Reading Skin Cancer’s Molecular Fingerprint

Machine-learning models analyzed Raman spectra to distinguish cancerous tissue from normal skin

October 6, 2026
2 min

Jama Network Open

Physician- and Practice-Level Variation in Clinical Trial Participation Among Patients With Advanced Cancer

The Medicine Maker

Building a Pre-Disease Data Map

Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear

October 7, 2026
2 min